Anzeige
Mehr »
Login
Samstag, 11.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Innocan Pharma News: Unfassbare Studie - LPT-Therapie bewahrt Patient vor dem Tod!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2JQN1 | ISIN: US76029N1063 | Ticker-Symbol: 7R8
Tradegate
09.05.24
10:13 Uhr
6,300 Euro
+0,350
+5,88 %
1-Jahres-Chart
REPLIMUNE GROUP INC Chart 1 Jahr
5-Tage-Chart
REPLIMUNE GROUP INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,8506,05010.05.
5,9006,00010.05.

Aktuelle News zur REPLIMUNE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.04.Replimune Group Inc: Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 86SAN DIEGO, April 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies...
► Artikel lesen
04.04.Replimune Group Inc: Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)115WOBURN, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies...
► Artikel lesen
26.03.Replimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEO1
26.03.Replimune Group announces CEO transition1
26.03.Replimune Group Inc: Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions104Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization Preparations on track to submit RP1 biologics...
► Artikel lesen
26.03.Replimune Group, Inc. - 8-K, Current Report1
08.02.Replimune Group: Q3 Earnings Insights2
08.02.Replimune Group, Inc. - 10-Q, Quarterly Report-
08.02.Replimune Group, Inc. - 8-K, Current Report-
08.02.Replimune Group Inc: Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update-
08.01.Replimune Group, Inc. - 8-K, Current Report2
28.12.23Replimune Group Inc: Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference4
27.12.23XFRA 7R8: WIEDERAUFNAHME/RESUMPTION304FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
26.12.23Replimune Group, Inc. - 8-K, Current Report1
06.12.23Barclays Maintains Overweight Rating for Replimune Group: Here's What You Need To Know4
06.12.23After Data Miss in Lead Cancer Indication, Replimune Maps Path for Oncolytic Virus5
05.12.23Why Is Replimune (REPL) Stock Down 48% Today?3
05.12.23Replimune shares halve as skin cancer drug fails to CERPASS phase 27
05.12.23Travere Therapeutics, Replimune among healthcare movers3
05.12.23What's Going On With Cancer-Focused Replimune Stock Today?6
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1